Blueprint Medicines, a Boston, MA-based developer of personalized cancer therapies, closed a $40m Series A financing.
The round was led by Third Rock Ventures.
The company intends to use the funds to develop new cancer therapies.
Founded in 2011 by Nicholas Lydon, Ph.D., Brian Druker, M.D., President and CEO Chris Varma, Ph.D., and CSO David Armistead, Ph.D., the company uses its Insights-to-Validation™ Platform and proprietary chemical library to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat.
In conjunction with the funding, Mark Levin and Alexis Borisy, partners at Third Rock Ventures, joined Blueprint’s board.